Influence of obesity on the outcome of non-surgical periodontal therapy - a systematic review

Fabienne A. Gerber¹, Philipp Sahrmann¹, Oliver A. Schmidlin², Christian Heumann³, Jürg Hans Beer² and Patrick R. Schmidlin¹*

Abstract
Background: Obesity and periodontitis are important chronic health problems. Obesity is associated with an increased prevalence of periodontitis. Whether obesity also affects the outcome of non-surgical periodontal therapy is to date still unclear.

Methods: A systematic review of studies referenced in SCOPUS, MEDLINE, PubMed, Cochrane, CINAHL, Biosis and Web of Science was performed. Titles, abstracts and finally full texts were scrutinized for possible inclusion by two independent investigators. Quality and heterogeneity of the studies were assessed and the study designs were examined. Probing pocket depth reduction was analyzed as primary surrogate parameter for therapeutic success after non-surgical periodontal therapy.

Results: One-hundred-and-fifty-nine potentially qualifying studies were screened. Eight studies fulfilled the inclusion criteria and were analyzed. Three of eight studies failed to show an influence of obesity on pocket depth reduction after non-surgical therapy. The remaining five studies documented a clear negative effect on the outcome of non-surgical periodontal therapy. The finally included studies did not correspond to the highest level of quality (RCTs). Due to the heterogeneity of the data a meta-analysis was not possible.

Conclusion: The literature on the effect of obesity on the treatment outcome of non-surgical periodontal therapy remains controversial. The data, however, support that obesity is not only a factor associated with poorer periodontal health but might also result in inferior response to non-surgical treatment of periodontitis.

Keywords: Obesity, Chronic periodontitis, Non-surgical periodontal therapy, Outcome

Background
The prevalence of obesity is increasing worldwide and is becoming one of the most important health hazards [1], as obesity is highly associated with increased overall morbidity and mortality [2].

Obesity is defined with a body mass index (BMI; body weight in kilogram divided by the square of the height in meters (kg/m²)) of at least 30.0 kg/m² [3], whereas overweight is defined with a BMI of 25–29.9 kg/m². Normal weight is characterized by a BMI ranging between 19 to 24.9 kg/m² [4]. In this context, BMI seems a valuable parameter to predict obesity-related disease risks in a wide range of populations [2]. There are, however, some limitations: Firstly, risk assessment by BMI is less applicable in persons over 65 years of age because they generally have a higher body fat content for the same BMI. Secondly, the abdominal (central, visceral, android) type of obesity, which is more often seen in men, is associated with higher morbidity than the rather female type of gluteofemoral (peripheral, gynoid) obesity and, thirdly, the BMI cut-off points for overweight and obesity are too high for Asian people [2]. In addition, current large studies have indicated that measurement of waist circumference (WC) or waist-to-hip-ratio (WHR) may be a better disease risk predictor than BMI [5, 6].
however, currently intensive research and debate as to whether BMI, WC, WHR, or all of them should be used to assess disease risk [2].

For the purpose of this systematic review, however, only BMI is the most frequently reported data of obesity in a large number of studies.

Adipose tissue contains usually 5-10 % macrophages, but the adipose tissue of obese patients shows up to 60 % macrophage infiltration [4]. Adipocytes secrete bioactive molecules called adipokines, that can modify or trigger inflammation and fat metabolism locally or systemically as signaling molecules to liver, muscle and endothelium [4]. Therefore, the adipose tissue can be considered as an important metabolically active endocrine organ [4].

This explains how obesity acts as a risk factor for several chronic diseases: Hypertension, type 2 diabetes, dyslipidemia, and coronary heart disease are so closely related to obesity that obesity itself is often considered to be a systemic disease. This disease also affects dental health [7]. Accordingly obese persons require attention of physicians and dentists [2].

Among dental pathologies, periodontitis is a very common, primarily bacterial inflammatory disease, which destroys teeth surrounding soft tissues and bone. It leads to pocket formation and ultimately to loss of teeth if no effective treatment is applied [8]. Periodontitis is no longer considered only an oral health issue but also a public health problem, as it constitutes a risk factor for cardiovascular conditions, poor glycemic control in diabetics and adverse outcome of pregnancy [4, 8]. These correlations coincide with obesity and general health.

Recently, it has been suggested that obesity is a possible risk factor for periodontitis [8]. One study identified obesity even as the second strongest risk factor for periodontitis preceded only by smoking [9]. The first report on the relationship between obesity and periodontal disease appeared in 1977. Perlstein and co-workers [10] found greater alveolar bone resorption in obese than in non-obese rats. Under healthy oral conditions, obesity itself did not promote periodontal damage, but in the presence of bacterial plaque accumulation periodontal inflammation was more severe in obese than in non-obese animals. With concomitant arterial hypertension, plaque accumulation caused even more pronounced periodontal destruction than with obesity alone. These results suggest that a combination of risk factors, such as the one defined by the metabolic syndrome, elicit a more severe periodontal effect [10, 11]. Chaffee et al. [12] found in their meta-analysis an increased prevalence odds ratio for obesity among subjects with periodontal disease of approximately one-third, a greater mean clinical attachment loss (CAL) among obese individuals, a higher BMI among subjects with periodontal disease, and a trend for linear increase in the odds of periodontal disease with increasing BMI [4, 12]. Finally the association reported between obesity and periodontitis was less strong than that reported between periodontal disease and adverse pregnancy outcomes [12, 13] or cardiovascular events [12, 14]. There seems, however, to be a stronger obesity-periodontitis association in women, non-smokers and younger individuals than in the general adult populations [12]. In addition, smoking remains another well-studied predisposing factor for periodontitis [12, 15, 16]. Thus, BMI and smoking share a complex relationship [17]. This relationship can be inverse in certain populations [12, 18, 19].

The biological mechanism by which obesity predisposes to periodontitis is not fully understood [8]. Compared to individuals with normal weight individuals with obesity have higher levels of circulating tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which are also secreted from adipose tissue and are involved in the pathophysiology of both obesity and periodontitis. Not surprisingly, serum levels of these cytokines decrease with loss of weight [20].

The objective of this systematic review was to study the hypothesis whether the clinical outcome, in terms of pocket depth reduction, after non-surgical periodontal therapy in non-obese is better than in obese individuals. To verify this hypothesis, we systematically reviewed all retrievable, qualitatively adequate clinical investigations, which focused on this topic.

Methods

The review was conducted according to the PRISMA criteria [21]. The research question was explored using the PICO method [22]. The focused question addressed was:

Does non-surgical periodontal therapy (I) have a different outcome in obese chronic periodontitis patients (P), than in non-obese chronic periodontitis patients (C), regarding periodontal pocket depth reduction as the main clinical periodontal parameter (O).

Search strategy and review process

An electronic search of SCOPUS, MEDLINE, PubMed, Cochrane, CINAHL, Biosis and Web of Science was carried out considering articles published up to January 2016 in English or German language. The search was performed in two steps. The first electronic search started at 20.11.14 and an update has been done at 5.1.16.

This is shown in Table 1. For the database search, a combination of subject headings (MeSH terms and CINAHL headings) and free text search was used. An example of a detailed strategy (Medline/OvidSP) is shown in Table 2.

The same search protocol was applied to all databases.
Two of the authors (FAG, PRS) screened the titles for potential eligibility according to the inclusion criteria. Based on the abstract screening, 18 studies were selected for full text review. Scores were independently allocated by both authors to each publication according to their suitability for the present review (see inclusion criteria). Any discrepancies were resolved by consensus.

**Inclusion criteria**

To be included studies had to be clinical interventional studies regarding the outcome of non-surgical periodontal therapy in obese or non-obese patients. The studies had to display the diagnosis of chronic periodontitis. Key parameters to be reported were data for pocket probing depth (PPD) and BMI.

**Exclusion criteria**

Studies were excluded for the following reasons: animal studies, case reports, commentaries, unsuitable exposure or outcome measures, confounding medical diagnoses (e.g. pregnancy or any systemic disease, such as diabetes, in addition to metabolic syndrome), confounding systemic medical treatments such as immunosuppressive treatments, cortisone or antibiotic treatment as well as confounding local treatments such as treatment of peri-mucositis, gingival overgrowth or surgical periodontal treatment. Studies including either the diagnosis of aggressive periodontitis or of peri-implantitis were excluded as well.

**Outcome measures**

The primary outcome measure is PPD after non-surgical periodontal treatment.

**Data extraction**

A list with exclusion reasons for each paper was generated. Total number of patients, demographic data, origin of study, outcome measurements 2, 3, 6 and 12 months after therapy and the impact of obesity on the treatment-outcome were extracted. In addition, the exact definition of chronic periodontitis, the assessment of the periodontal disease and the number of smokers included in the studies were summarized. Data on the individual definition of obesity and the systemic examinations were also collected. Non-surgical periodontal treatment measures, treatment time, periodontal maintenance and adverse events were also recorded for each study separately (Tables 3, 4, 5, 6 and 7).

The quality of the included studies was assessed through the Newcastle-Ottawa Quality Assessment Scale (Table 8).

**Results**

**Selection of studies**

Initially, 159 studies were identified by electronic search by the two reviewers (FAG, PRS). Full text analysis of the 18 potentially qualified reports led to exclusion of 10 other studies. Additional five titles [23–27] were identified by hand search but after full text analysis, all these articles had to be excluded based on the inclusion and exclusion criteria.

### Table 1

Search protocols with the respective number of references dated from November 11 2014 (1) and January 1 2016 (2)

| Database        | References 1 & 2 | References after deduplication 1 & 2 |
|-----------------|-----------------|--------------------------------------|
| Scopus          | 40 + 14         | 9 + 5                                |
| Medline         | 42 + 8          | 39 + 7                               |
| PubMed          | 6 + 11          | 2 + 11                               |
| Cochrane        | 12 + 2          | 2 + 1                                |
| CINAHL          | 48 + 15         | 42 + 13                              |
| Biosis          | 25 + 7          | 10 + 1                               |
| Web of Science  | 38 + 13         | 16 + 1                               |
| Pool            | 211 + 70        | 120 + 39                             |

After deduplication 159 references

### Table 2

Medline search strategy

| Step | Query                                                                 | Hits  |
|------|-----------------------------------------------------------------------|-------|
| 1    | Exp Periodontitis/AND (adult OR chronic*).ti,ab.                     | 5703  |
| 2    | Chronic periodontitis/OR periodontal pocket/                          | 7004  |
| 3    | 2 OR 3                                                               | 10454 |
| 4    | (adult OR chronic*) adj3 periodontiti*).ti,ab.                       | 5352  |
| 5    | (attachment adj3 loss).ti,ab. AND ((clinical OR periodontal) adj3 attachment).ti,ab. | 1305  |
| 6    | (periodontal adj3 pocket).ti,ab.                                     | 1066  |
| 7    | OR/3-7                                                               | 12910 |
| 8    | Dental scaling/ OR "root planing"/                                   | 3479  |
| 9    | (subgingival OR root OR supragingival) adj3 (scaling* OR planing*).ti,ab. | 2288  |
| 10   | (deep adj3 (scaling* OR cleaning)).ti,ab.                            | 62    |
| 11   | ((conventional OR initial OR "non surgical" OR nonsurgical) adj3 (treatment OR therapy)).ti,ab. | 33417 |
| 12   | OR/8-11                                                              | 37131 |
| 13   | 7 AND 12                                                             | 2184  |
| 14   | Exp Obesity/                                                          | 154540|
| 15   | Exp Body Weight/                                                     | 369850|
| 16   | (overweight OR obese OR obesity OR adipositi* OR BMI OR "body mass index").ti,ab. | 300847|
| 17   | (cardiolipin OR lipid* OR leptin).ti,ab.                             | 395517|
| 18   | "waist to hip".ti,ab.                                               | 9048  |
| 19   | (body adj3 weight).ti,ab.                                            | 163760|
| 20   | OR/14-19                                                             | 954233|
| 21   | 13 AND 20                                                           | 42    |

The asterisk represents a wildcard and can be used in all search fields that allow words and phrases.
| Excluded studies | Reason for exclusion |
|------------------|----------------------|
| Europerio 4 2003 [37] | Not addressing research question |
| Abstracts for the Royal Australian and New Zealand College of Psychiatrists 2005 [38] | Not addressing research question |
| 5th Joint Meeting of the European Tissue Repair Society and the Wound Healing Society 2009 [39] | Not addressing research question |
| Recently published abstracts [40] | Not addressing research question |
| DENTSPLY Posters 2012 [41] | Not addressing research question |
| HealthBeat 2007 [42] | Not addressing research question |
| Abstracts for Poster Presentations 2011 [43] | Not addressing research question |
| Abstracts for the International Symposium on Dental Hygiene 2013 [44] | Not addressing research question |
| Abou Sulaiman et al. 2010 [45] | Not addressing research question |
| Acharya et al. 2010 [46] | No PPD reduction data |
| Akpinar et al. 2013 [47] | Not addressing research question |
| Altay et al. 2013 [20] | No PPD reduction data |
| Armstrong et al. 2010 [48] | Not addressing research question |
| Arora et al. 2013 [49] | Not addressing research question |
| Basegmez et al. 2011 [50] | Not addressing research question |
| Bresolin et al. 2013 [51] | Not addressing research question |
| Bresolin et al. 2014 [52] | Not addressing research question |
| Casperson et al. 2012 [53] | Not addressing research question |
| Caula et al. 2014 [54] | No comparison |
| Caula et al. 2014 [54] | Duplicate |
| Chapple et al. 2006 [55] | Not addressing research question |
| Chapple et al. 2007 [56] | Not addressing research question |
| Chandni et al. 2015 [57] | Not addressing research question |
| Chaston et al. 2014 [58] | Not addressing research question |
| Chee et al. 2008 [59] | Inclusion of diabetes |
| Chee et al. 2013 [60] | Missed intervention, inclusion of diabetes |
| Chen et al. 2012 [61] | Inclusion of diabetes |
| D’Aiuto et al. 2004 [62] | Not addressing research question |
| D’Aiuto et al. 2004 [63] | Not addressing research question |
| D’Aiuto et al. 2005 [23] | No comparison |
| D’Aiuto et al. 2006 [64] | Not addressing research question |
| Deppe et al. 2010 [65] | Not addressing research question |
| Dodington et al. 2015 [66] | No obesity data |
| Draper et al. 2010 [67] | Not addressing research question |
| Duan et al. 2009 [24] | Written in Chinese |
| Edwards et al. 2006 [68] | Not addressing research question |
| Efurd et al. 2012 [69] | Not addressing research question |
| Elliott-Smith et al. 2011 [70] | Not addressing research question |
| Engebretnson et al. 2014 [71] | Not addressing research question |
| Fairfield et al. 2010 [72] | Not addressing research question |
| Fang et al. 2015 [73] | Inclusion of end-stage renal disease patients |
| Fentoglu et al. 2010 [74] | Statin intake |
| Fine et al. 2007 [75] | Not addressing research question |
| Fokkema et al. 2012 [76] | Not addressing research question |
| Fu et al. 2015 [77] | No comparison |
| Garcia et al. 2010 [78] | Not addressing research question |
| Giblin et al. 2014 [79] | Inclusion of prediabetes |
| Giblin et al. 2014 [79] | Duplicate |
| Gluch et al. 2007 [80] | Inclusion of diabetes |
| Goldie et al. 2002 [81] | Not addressing research question |
| Goldie et al. 2004 [82] | Not addressing research question |
| Goldie et al. 2005 [83] | Not addressing research question |
| Griffin et al. 2012 [84] | Not addressing research question |
| Gurenlian et al. 2006 [85] | Not addressing research question |
| Gurenlian et al. 2009 [86] | Not addressing research question |
| Hammaker et al. 2010 [87] | Not addressing research question |
| Horwitz et al. 2007 [88] | Not addressing research question |
| Hovliaras-Delozier et al. 2008 [89] | Not addressing research question |
| Ide et al. 2004 [90] | No obesity data |
Table 3 Excluded studies (Continued)

| Reference                        | Reason for Exclusion |
|----------------------------------|----------------------|
| Ide et al. 2007 [91]             | Not addressing research question |
| Iwamoto et al. 2003 [25]         | Application of antibiotics |
| Jahn et al. 2004 [92]            | Not addressing research question |
| Jahn et al. 2015 [93]            | Not addressing research question |
| Jaiswal et al. 2015 [94]         | No treatment (SRP) |
| Janket et al. 2014 [95]          | Meta-analysis |
| Janket et al. 2015 [96]          | Duplicate |
| Jared et al. 2008 [97]           | Not addressing research question |
| Jiang et al. 2013 [98]           | Not addressing research question |
| Kamil et al. 2011 [99]           | No obesity data |
| Kamilov et al. 1998 [100]        | Not addressing research question |
| Kapellas et al. 2013 [101]       | No obesity data |
| Kardesler et al. 2010 [102]      | Inclusion of diabetes |
| Keller et al. 2015 [103]         | Systematic review |
| Kiani et al. 2014 [104]          | No obesity data |
| Kiany et al. 2015 [105]          | Duplicate |
| Kipp et al. 2003 [106]           | Not addressing research question |
| Kudva et al. 2010 [107]          | Inclusion of diabetes |
| Kumar et al. 2015 [108]          | Inclusion of diabetes |
| Kurt et al. 2007 [109]           | Not addressing research question |
| Kurt et al. 2007 [110]           | Duplicate |
| Li et al. 2013 [111]             | Not addressing research question |
| Li et al. 2013 [112]             | No obesity data |
| Ling et al. 2012 [113]           | Inclusion of diabetes |
| Lo et al. 2011 [114]             | Not addressing research question |
| Malhotra et al. 2012 [115]       | Not addressing research question |
| Mancl et al. 2013 [116]          | Supplementation of ω-3 eicosapetanoic acid |
| Martinec et al. 2014 [117]       | One year of omega-3 supplementation |
| Matlock et al. 2012 [118]        | No treatment (SRP) |
| McDaniel et al. 2013 [119]       | Not addressing research question |
| Mehwanwade et al. 2014 [120]     | Local drug delivery |
| Merchant et al. 2014 [121]       | Inclusion of diabetes |
| Michalowicz et al. 2014 [122]    | Inclusion of diabetes |

Table 3 Excluded studies (Continued)

| Reference                        | Reason for Exclusion |
|----------------------------------|----------------------|
| Mizra et al. 2006 [123]          | Not addressing research question |
| Moeintaghavi et al. 2012 [124]   | Inclusion of diabetes |
| Moravek et al. 2011 [125]        | No treatment (SRP) |
| Muthu et al. 2015 [126]          | No obesity data |
| Nassar et al. 2012 [127]         | Inclusion of diabetes |
| Newton et al. 2011 [128]         | Not addressing research question |
| Nichols et al. 2001 [129]        | Not addressing research question |
| Novakovic et al. 2013 [130]      | Not addressing research question |
| Novakovic et al. 2014 [131]      | Not addressing research question |
| Oliveira et al. 2011 [132]       | Not addressing research question |
| Olsen et al. 2006 [133]          | Not addressing research question |
| Paquette et al. 2008 [134]       | No obesity data |
| Perayil et al. 2014 [135]        | Duplicate |
| Perayil et al. 2014 [136]        | Not addressing research question |
| Phillips et al. 2013 [137]       | Not addressing research question |
| Pradeep et al. 2007 [138]        | Not addressing research question |
| Price et al. 2010 [139]          | Not addressing research question |
| Qiqiang et al. 2012 [140]        | No obesity data |
| Radafshar et al. 2012 [141]      | Not addressing research question |
| Radnai et al. 2009 [142]         | Not addressing research question |
| Raghavendra et al. 2012 [143]    | Not addressing research question |
| Ramirez et al. 2011 [144]        | No obesity data |
| Rasch et al. 1995 [145]          | Not addressing research question |
| Sadatmansouri et al. 2006 [146]  | Not addressing research question |
| Safi et al. 2013 [147]           | Inclusion of patients with coronary disease |
| Safi et al. 2013 [148]           | Duplicate |
| Sembene et al. 2000 [149]        | Inclusion of patients with coronary artery disease |
| Shrivastava et al. 2010 [150]    | Not addressing research question |
criteria (Table 3). Therefore, eight publications [8, 28–34] from the electronic and hand search fulfilled the criteria. However, it was not possible to compare the raw data so that we had to reduce our analysis to a qualitative analysis. This process is summarized in a flow-chart (Fig. 1).

Table 3 Excluded studies (Continued)

| Publication                  | Type             |
|------------------------------|------------------|
| Sgolastra et al. 2013 [36]   | Meta-Analysis    |
| Shimada et al. 2010 [151]    | No comparison    |
| Shimoe et al. 2011 [152]     | Case report      |
| Singh et al. 2014 [153]      | Not addressing research question |
| Siqueira et al. 2013 [154]   | Not addressing research question |
| Stewart et al. 2001 [155]    | Inclusion of diabetes |
| Talbert et al. 2006 [156]    | Inclusion of diabetes |
| Tamaki et al. 2009 [157]     | No obesity data  |
| Tamaki et al. 2011 [158]     | No obesity data  |
| Tawfig et al. 2015 [159]     | No comparison    |
| Teles et al. 2012 [160]      | No comparison    |
| Toker et al. 2012 [161]      | Not addressing research question |
| Tuter et al. 2007 [162]      | Inclusion of patients with systemic disease |
| Vardar et al. 2003 [163]     | Not addressing research question |
| Van Dyke et al. 2015 [164]   | Not addressing research question |
| Vyas et al. 2000 [165]       | Not addressing research question |
| Wahid et al. 2013 [166]      | Not addressing research question |
| Wang et al. 2013 [167]       | Inclusion of aggressive periodontitis |
| Wehmeyer et al. 2013 [168]   | Not addressing research question |
| Wei et al. 2010 [169]        | No obesity data  |
| Williams et al. 2007 [148]   | No obesity data  |
| Williams et al. 2009 [170]   | Not addressing research question |
| Williams et al. 2009 [171]   | Not addressing research question |
| Wood et al. 2006 [172]       | Not addressing research question |
| Wu et al. 2015 [173]         | Not addressing research question |
| Zare et al. 2014 [174]       | Not addressing research question |
| Zhou et al. 2013 [175]       | Inclusion of patients with systemic disease |
| Zuza et al. 2011 [176]       | No PPD reduction data |

Summary of studies: characteristics (PICO)

Total number of patients, demographic data, origin of study, outcome measurements 2, 3, 6 and 12 months after therapy and the impact of obesity on the treatment-outcome are summarized in Table 4.

Definition of chronic periodontitis, periodontal assessment and the amount of smokers included are depicted in Table 5.

The definition of obesity and systemic examination were summarized in Table 6. Non-surgical periodontal treatment, treatment time, periodontal maintenance and limitations are shown in Table 7.

Population

Of the eight finally analyzed studies, clinical trials comprised 516 participants. One study [8] enrolled only women. The prevalence of smoking among male patients affected with periodontitis was so high that Al-Zahrani and co-workers [8] were unable to correct for smoking in the male population. Accordingly, only women were included in their study. Overall the studies comprised between 26 up to 260 subjects (Table 4).

The inclusion criteria “age” was defined in all but one study [30]. Three investigations [28, 33, 34] defined the age ≥18 years. The other studies defined a minimum age of 30 years [31, 32] or 35 years [8]. Duzagac et al. defined an age range from 25 to 55 years (Table 4).

Suvan et al. [34] included smokers into their study. Lakkis et al. [33] and Eldin et al. [30] did not mention the smoking status of the patients. All other studies [8, 28, 29, 31, 32] excluded smokers (Table 5).

Patients with diabetes, another important modifier of periodontal health or disease [35] were excluded in seven studies [8, 28–32, 34]. Lakkis et al. [33] did not report the presence or absence of diabetes.

Intervention/Comparison

Each paper described the periodontal intervention as a non–surgical therapy. All studies [8, 28–34] applied scaling and root planing. Ultrasonic instruments and/or hand instruments were used in all studies (Table 7).

Two papers [8,34] reassessed the PPD 2 months after therapy. Two studies [29, 30] reassessed their patients after 3 months. Another two papers [28, 31] re-evaluated the patients after 3 and 6 months and one study [32] reassessed the PPD three, six and 12 months after therapy. Only Lakkis et al. [33] measured the periodontal pocket depths already 4 to 6 weeks after nonsurgical therapy (Table 3). Oral hygiene was instructed additionally to the non–surgical periodontal therapy in all studies (Table 7).

Due to the heterogeneity of the study designs with respect to outcome measures and treatment protocol, as well as variation in study population, sample size, and/or
Table 4 Probing pocket depth (PPD [mm]) as primary outcome variable

| Author & year | Total number of patients | Outcome after 2 months | Outcome after 3 months | Outcome after 6 months | Outcome after 12 months | Impact of obesity on the treatment – outcome mean – reduction of PPD (± SD) |
|---------------|--------------------------|------------------------|------------------------|------------------------|-------------------------|--------------------------------------------------|
|               | Age (mean ± SD)          | at baseline – mean (± SD) at reassessment | at baseline – mean (± SD) at reassessment | at baseline – mean (± SD) at reassessment | at baseline – mean (± SD) at reassessment |                                                                 |
| Al – Zahrani  | 40 (only women)          | Total sample: 2.65 (±0.47) – 2.44 (±0.41) | n.r.                   | n.r.                   | n.r.                   | Normal-weight: 0.19 (±0.27) Obese: 0.23 (±0.33) p-value = 0.663 (n. sig.) |
| et al. 2012  | Normal-weight: 20        | Age: 43.4 (±7.8)        | Normal-weight: 3.33 (±0.92) – 2.71 (±0.40) | 3.33 (±0.92) – 2.71 (±0.40) | n.r. | Summary of Multivariable Analysis Results (Coefficient, 95 % CI): a %PD > 5mm after 3 months to obese (Model 2): p-value = 0.02 a %PD > 5mm after 6 months to obese (Model 2): p-value = 0.005 Nb »PD > 2mm after 3 months to Obese (Model 2): p-value = 0.02 Nb »PD > 2mm after 6 months to Obese (Model 2): p-value = 0.06 (n.sig.) |
| Bouaziz et al.| 36                       | Normal-weight: 51.00 (±13.1) | n.r.                   | Normal-weight: 3.33 (±0.92) – 2.71 (±0.40) | n.r. |                                                                 |
| 2015 [28]     | Obese: 18                | Age: 51.3 (±16.7)       | p-value: n. sig.       | p-value: n. sig.       | p-value: n. sig.       |                                                                 |
|               | Range from 22 to 78      | Country: Saudi Arabia   |                                                                 |                                                                 |                                                                 |                                                                 |
|               | Normal-weight periodontally healthy control subjects (PHNW): 15 |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |
|               | Obese patients with periodontitis (CPO): 15                    |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |
|               | Normal weight patients with periodontitis (CPNW): 15            |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |
|               | Age: Range from 28 to 52 |                                                                 |                                                                 |                                                                 |                                                                 |                                                                 |
|               | CPNW: 41.06 (±7.10)      | p-value: 0.001          | Baseline: CPO: 1706    | CPO: 1706              |                                                                 |                                                                 |
|               | CPO: 40.66 (±7.98)       | p-value: 0.001          | CPO: 1706              | CPO: 1706              |                                                                 |                                                                 |
|               | PHNW: 39.66 (±6.53)      | p-value: 0.001          | CPNW: 1766             | CPNW: 1766             |                                                                 |                                                                 |
|               | p-value: n. sig.         | p-value: 0.001          | 3 months: CPO: 2214    | CPO: 2214              |                                                                 |                                                                 |
| Duzagac et al.| 45                       | Normal weight patients with periodontitis (CPNW): 15 | CPNW: 3.19 (±0.38) – 2.51 (±0.06) | 3.19 (±0.38) – 2.51 (±0.06) | n.r. | Number of sites with PD < 4 mm: Baseline: CPO: 1706 CPNW: 1766 3 months: CPO: 2214 CPNW: 2206 |
| 2015 [29]     | Obese patients with periodontitis (CPO): 15                     | p-value: 0.001          | CPO: 1706              | CPO: 1706              |                                                                 |                                                                 |
|               | Normal weight periodontally healthy control subjects (PHNW): 15 | p-value: 0.001          | CPNW: 1766             | CPNW: 1766             |                                                                 |                                                                 |
|               | Age: Range from 28 to 52 |                                                                 | 3 months: CPO: 2214    | CPO: 2214              |                                                                 |                                                                 |
|               | CPNW: 41.06 (±7.10)      | p-value: 0.001          | CPO: 1706              | CPO: 1706              |                                                                 |                                                                 |
|               | CPO: 40.66 (±7.98)       | p-value: 0.001          | CPNW: 1766             | CPNW: 1766             |                                                                 |                                                                 |
|               | PHNW: 39.66 (±6.53)      | p-value: 0.001          | 3 months: CPO: 2214    | CPO: 2214              |                                                                 |                                                                 |
|               | p-value: n. sig.         | p-value: 0.001          | CPO: 1706              | CPO: 1706              |                                                                 |                                                                 |
|               | Country: Turkey          | p-value: 0.001          | CPNW: 1766             | CPNW: 1766             |                                                                 |                                                                 |
|               | % of sites with PD < 4 mm: Baseline: CPO: 1706 CPNW: 1766 3 months: CPO: 2214 CPNW: 2206 | p-value: 0.001          | 3 months: CPO: 2214    | CPO: 2214              |                                                                 |                                                                 |
|               | % of sites with PD ≥ 4 mm: Baseline: CPO: 1706 CPNW: 1766 3 months: CPO: 2214 CPNW: 2206 | p-value: 0.001          | 3 months: CPO: 2214    | CPO: 2214              |                                                                 |                                                                 |

Note: n.r. = not reported.
| Study               | Total number of patients | Overweight: n.r. | Obese: n.r. | With obesity: n.r. | Without obesity: n.r. | p-value | With obesity: n.r. | Without obesity: n.r. | p-value |
|---------------------|--------------------------|------------------|-------------|-------------------|-----------------------|---------|-------------------|-----------------------|---------|
| Eldin et al. 2013   | Total number of patients: 26 | Overweight: 0.6 (±1.29) | 0.75 (±2.12) | p-value: n.r. | Obese: 3.15 (±2.43) – 1.59 (±2.34) | p-value: n.r. | Overweight: 0.784 | Obese: 0.209 | p-value = 0.326 (n. sig.) |
|                     | Overweight: 12 |                      |             |                   |                       |         |                   |                       |         |
|                     | Obese: 14 |                      |             |                   |                       |         |                   |                       |         |
|                     | Age: Range from 35 to 48 |                      |             |                   |                       |         |                   |                       |         |
|                     | Country: Egypt |                      |             |                   |                       |         |                   |                       |         |
| Gonçalves et al. 2015 | Total number of patients: 39 | Without obesity: 3.4 (±0.6) – 3.0 (±0.5) | p-value: sig. | With obesity: 3.6 (±0.6) – 3.3 (±0.5) | p-value: sig. | Without obesity: 3.4 (±0.6) – 2.7 (±0.6) | p-value: sig. | Without obesity: 3.4 (±0.6) – 2.9 (±0.5) | p-value: sig. |
|                     | Without obesity: 21 |                      |             |                   |                       |         |                   |                       |         |
|                     | With obesity: 18 |                      |             |                   |                       |         |                   |                       |         |
|                     | Age: Without obesity: 48.4(±9.5) |                      |             |                   |                       |         |                   |                       |         |
|                     | With obesity: 48.8 (±9.5) |                      |             |                   |                       |         |                   |                       |         |
|                     | p-value= 0.08 (n. sig.) |                      |             |                   |                       |         |                   |                       |         |
|                     | Country: Brazil |                      |             |                   |                       |         |                   |                       |         |
|                     | n.r. |                      |             |                   |                       |         |                   |                       |         |
| Gonçalves et al. 2015 | Total number of patients: 40 | Non-obese: 3.4 (±0.6) – 2.9 (±0.5) | p-value: sig. | Obese: 3.6 (±0.6) – 3.3 (±0.5) | p-value: sig. | Non-obese: 3.4 (±0.6) – 2.7 (±0.6) | p-value: sig. | Non-obese: 3.4 (±0.6) – 2.6 (±0.6) | p-value: sig. |
|                     | Non-obese: 20 |                      |             |                   |                       |         |                   |                       |         |
|                     | Obese: 20 |                      |             |                   |                       |         |                   |                       |         |
|                     | Age: Non-obese: 48.5 (±9.3) |                      |             |                   |                       |         |                   |                       |         |
|                     | Obese: 50.0 (±4.5) |                      |             |                   |                       |         |                   |                       |         |
|                     | p-value = 0.52 (n. sig.) |                      |             |                   |                       |         |                   |                       |         |
|                     | Country: Brazil |                      |             |                   |                       |         |                   |                       |         |
|                     | n.r. |                      |             |                   |                       |         |                   |                       |         |

Table 4 Probing pocket depth (PPD [mm]) as primary outcome variable (Continued)
| Study                | Total number of patients: | Probing pocket depth (PPD [mm]) as primary outcome variable (Continued) |
|----------------------|---------------------------|-----------------------------------------------------------------------|
| Lakkis et al. 2011 [33] | 30                        | Total number of patients: 30  
Surgery: 15  
Control: 15  
Age:  
Surgery: 45.6 (±11.1)  
Control: 48.5 (±12.0)  
p-value = 0.778 (n. sig.)  
Country: USA (Cleveland, Ohio)  
4-6 weeks after therapy!  
Surgery: 2.6 (±0.6) – 2.2 (±0.5)  
p-value < 0.001  
Control: 3.1 (±0.8) – 2.8 (±0.7)  
p-value < 0.001 |
| Suvan et al. 2014 [34]  | 260                       | Total number of patients: 260  
Normal: 112  
Overweight: 93  
Obese: 55  
Age:  
Normal: 46.30 (±8.38)  
Overweight: 47.27 (±8.93)  
Obese: 46.55 (±6.87)  
p-value = 0.701 (n. sig.)  
Country: Great Britain (London)  
Summary of univariable GEE Analysis Results  
(Coefficient, 95 % CI):  
BMI (kg/m²) to PPD at 2 months  
p-value = 0.055  
Overweight to PPD at 2 months  
p-value = 0.372 (n. sig.)  
Obese to PPD at 2 months  
p-value = 0.0064 (n. sig.)  
Summary of Multivariable GEE Analysis Results  
(Coefficient, 95 % CI):  
BMI (kg/m²) to PPD at 2 months  
p-value = 0.013  
Overweight to PPD at 2 months  
p-value = 0.63 (n. sig.)  
Obese to PPD at 2 months  
p-value = 0.031 |

*CI* confidence interval, CPNW normal weight patients with periodontitis, CPO obese patients with periodontitis, kg kilogram, m meter, mm millimeter, Nb a PD number of improving PD, n.r. not reported, PD probing depth, PHNW normal weight periodontally healthy control subjects, PPD periodontal pocket depth, p probability, SD standard deviation, (n.) sig. (not) significant, stat. statistically, WHO world health organisation
statistical methods, a statistical synthesis of the results of the included studies was not possible. So the authors decided to analyze the papers on a qualitative way [22]. A meta-analysis was not possible. Three [8, 29, 30] of the eight papers [8, 28–34] reported no major negative impact of obesity on response to periodontal therapy in terms of PPD reduction (mm). Al-Zahrani et al. [8] assessed the reduction of PPD (mm) comparing obese with normal–weighted women. There was no statistically significant effect of obesity on treatment outcome. Duzagac et al. [29] assessed the clinical response to non-surgical periodontal treatment,

| Table 5 Definition of periodontitis, periodontal assessment and definition of smoking |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Author & year       | Definition of chronic periodontitis            | Periodontal assessment                        | Smokers                                      |
|---------------------|------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Al-Zahrani et al. 2012 [8] | ≥ 20 teeth, CAL ≥ 3 mm at ≥ 30 of the sites (generalized moderate/severe chronic periodontitis) | Full-mouth periodontal examination on all teeth excluding 3rd molars and partially erupted teeth | Smokers excluded |
| Bouaziz et al. 2015 [28] | ≥ 12 teeth, ≥ 30 % of sites with CAL ≥ 3 mm (moderate-to-severe generalized chronic periodontitis) | Full-mouth clinical measurements included the following: 1) PI, 2) BOP, 3) PD (mm), 4) CAL (mm), PI, BOP, PD, and CAL measurements were performed using a manual periodontal probe at 6 sites per tooth, PD was defined as the distance from the free gingival margin to the bottom of the pocket/sulcus, and CAL was defined as the distance from the cemento-enamel junction to the bottom of the pocket/sulcus | Non-smoker or former smoker since ≥ 5 years |
| Duzagac et al. 2015 [29] | ≥ 20 teeth, PD ≥ 4 mm in ≥ 30 % of periodontal sites, BOP in ≥ 50 % of periodontal sites, interproximal CAL > 2 mm in ≥ 20 % of periodontal sites, radiographic evidence of bone loss, as described by Armitage [177] | A Williams-type periodontal probe (UNC15, Hu-Friedy, Chicago, IL, USA) was used for the measurements of periodontal parameters, including PI (Silness–Löe) [178], GI (Löe–Silness) [179], BOP, PD and CAL, all clinical periodontal measurements were performed at 6 sites per tooth (mesiobuccal, mid-buccal, distobuccal, mesiolingual, mid-lingual and distolingual), excluding third molars | Smokers excluded |
| Eldin et al. 2013 [30] | n.r. (chronic periodontitis) | Full-mouth, 4 sites per tooth (mesio-buccal, mid-buccal, disto-buccal, mid-lingual) around each tooth | n.r. |
| Gonçalves et al. 2015 [31] | ≥ 15 teeth excluding 3rd molars and teeth with advanced decay indicated for exodontia, > 30 % of the sites with concomitant PD and CAL ≥ 4 mm and a minimum of 6 teeth distributed in the different quadrants presenting at least one site with PD and CAL ≥ 5 mm and BOP at baseline (generalized chronic periodontitis) | 6 sites per tooth on all teeth excluding 3rd molars (distance between the gingival margin and the bottom of the sulcus/pocket [mm]) | Smokers excluded |
| Gonçalves et al. 2015 [32] | ≥ 15 teeth excluding 3rd molars and teeth with advanced decay indicated for exodontia, > 30 % of the sites with concomitant PD and CAL ≥ 4 mm and a minimum of 6 teeth distributed in the different quadrants presenting at least one site with PD and CAL ≥ 5 mm and BOP at baseline (generalized chronic periodontitis) | 6 sites per tooth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual) excluding third molars, with a manual periodontal probe (UNC15, Hu-Friedy, Chicago, IL, USA) | Current smokers excluded, smoking within the past 10 years excluded |
| Lakkis et al. 2011 [33] | ≥ 20 teeth, mean CAL ≥ 2 mm (chronic periodontitis) | 6 sites per tooth | n.r. |
| Suvan et al. 2014 [34] | PD ≥ 5 mm and marginal alveolar bone loss > 30 % with > 50 % of the teeth affected (generalized severe periodontitis) | 6 sites per tooth on all teeth present | Normal-group = 47 % smokers, Overweight-group = 25 % smokers, Obese-group = 15 % smokers, p-value = 0.0045 (sig. on p ≤ 0.05) |

BOP bleeding on probing, CAL clinical attachment level, GI gingival index, mm millimeter, n.r. not reported, p probability, PD probing depth, PI plaque index, sig. significant

Outcome
Generally obese patients were found to have deeper periodontal pockets at baseline in all studies.
Table 6: Definition of obesity and systemic examination

| Author & year | Definition of obesity | Systemic examination |
|---------------|-----------------------|----------------------|
| Al – Zahrani et al. 2012 [8] | Normal-weight: BMI: 18.5 to < 25 kg/m² Obese: BMI ≥ 30 kg/m² | Weight in kilograms and height in meters were measured; BMI: (weight/height² [kg/m²]) |
| Bouazziz et al. 2015 [28] | Normal-weight: BMI ≥ 18.5 kg/m² and ≤ 25 kg/m² Obese: BMI ≥ 30 kg/m² | Weight (kg), height (m), waist/hip circumferences (cm) 
weight was obtained using a calibrated scale, 
hair was measured using a measuring board, 
BMI: (weight/height² [kg/m²]), 
waist measurements were taken at the level of the umbilicus (cm) 
Hip measurements were taken at the greatest circumference with a measuring tape, 
WHR: ratio of waist to hip circumference |
| Duzagac et al. 2015 [29] | Normal-weight (CPNW): n.r. Obese (CPO): BMI ≥ 30 % and WHR > 0.95 for males and 0.80 for females | One trained examiner performed all anthropometric measurements: weight (kg), height (m), waist (cm), hip (cm), BMI: (weight/height² [kg/m²]), WHR: ratio of waist to hip circumference, anthropometric measurements were repeated before the final follow-up visit to assess whether there was any change in BMI or WHR n.r. |
| Eldin et al. 2013 [30] | Overweight: BMI: 25-29.9 kg/m² Obese: BMI ≥ 30 kg/m² According to the WHO (3) | BMI: (weight/height² [kg/m²]) WHR: ratio of waist to hip circumference |
| Gonçalves et al. 2015 [31] | Without obesity: BMI 20-29.9 kg/m² and WHR < 0.85 for females and < 0.9 for males With obesity: BMI ≥ 30 kg/m² and WHR ≥ 0.9 for females and WHR ≥ 0.9 for males Non-obese: BMI: 20-24.9 kg/m² and WHR below that determined for obesity (i.e. WHR < 0.85 for women and WHR < 0.90 for men) (World Health Organization 2008) Obese: BMI ≥ 30 and ≥ 40 kg/m² and concomitant WHR ≥ 0.85 for women and WHR ≥ 0.90 for men. | One trained examiner performed all anthropometric measurements: weight (kg), height (m), waist (cm) and hip circumferences (cm) BMI: (weight/height² [kg/m²]), WHR: ratio of waist to hip circumference, anthropometric measurements were reassessed at all follow-up visits to verify that the patients did not change their obese or non-obese status during the course of the study |
| Lakkis et al. 2011 [33] | Control: obese (BMI ≥ 30 kg/m²) Did not have the bariatric surgery nor did they lose weight to serve as a control group Surgery: obese (BMI ≥ 30 kg/m²) and ≥ 40 % loss of their excess weight at ≥ 6 months after bariatric surgery | BMI: (weight/height² [kg/m²]) Percentage of weight loss after BS |
| Suvan et al. 2014 [34] | Normal: BMI: 18.5-24.9 kg/m² Overweight: BMI: 25-29.9 kg/m² Obese: BMI ≥ 30 kg/m² | BMI: (weight/height² [kg/m²]) Based upon height and weight of the individual measured with a wall-mounted height measure and mechanical scales |

BF body fat, BMI body mass index, BS bariatric surgery, cm centimeter, CPNW normal weight patients with periodontitis, CPO obese patients with periodontitis, HDL high-density lipoprotein, kg kilogram, m meter, n. r. not reported, WC waist circumference, WHO world health organization, WHR waist-hip-ratio

According to the severity of periodontitis based on probing depth < 4 mm vs. ≥ 4 mm. Patients with and without obesity showed similar clinical healing in terms of percentage and number of sites with probing depth < 4 mm and ≥ 4 mm. So they failed to show an effect of obesity on the treatment outcome dependent on the severity of the disease. Eldin et al. [30] also found no effect when comparing an overweight group with an obese group. The difference between the groups in reduction of PPD was not significant (Table 4).

Five [28, 31–34] of the eight papers showed a negative effect of obesity on the healing after non-surgical periodontal therapy. Bouazziz et al. [28] revealed that normal-weight patients had a better response to periodontal treatment than obese patients. This effect was specially observed for moderate-to-deep pockets. This fact suggests that the more severe the periodontitis the more pronounced is the negative effect of obesity on periodontal treatment outcome. They showed in the multivariate analysis that obesity was significantly associated with percentage changes of PD > 5 mm and numbers of improving sites (p ≤ 0.05). In the univariate analysis all periodontal parameters improve more in patients suffering from more severe periodontitis at baseline. Other patient characteristics, like age, sex, obesity, and WHR, were not associated with periodontal parameter changes. Gonçalves et al. [31] showed that patients with obesity and chronic periodontitis had a lower PDD reduction than patients without obesity. The measurement of the
| Author & Year | Non-surgical periodontal treatment | Treatment time; periodontal maintenance | Limitations |
|---------------|----------------------------------|----------------------------------------|-------------|
| Al – Zahrani et al. 2012 [8] | Oral hygiene instructions, SRP performed by one operator | n.r.; n.r. | n.r. |
| Bouaziz et al. 2015 [28] | Oral hygiene instructions (brushing technique: Bass technique, use of interproximal hygiene devices, CHX mouthwash (0.12 %) twice a day for 7 days), SRP under local anesthesia using an ultrasonic device and manual curets, aim of each session was to remove biofilms and calculus of scaled roots, treatment protocol did not include antibiotic treatment, all treatments procedures were performed by the same periodontist (WB) | 2-3 sessions for probing depth (PD) > 5 mm lasting 1 h each within 7 days; Oral hygiene was controlled at each appointment, hygiene instructions were repeated if needed at the 3-month examination, reinstruction of oral hygiene methods was performed if needed, and residual pockets ≥ 4 mm were systematically scaled and planed | During the study, two patients dropped out in each group for the following reasons: 1) two patients migrated; 2) one missed the 3-month examination; 3) one missed the final examination |
| Duzagac et al. 2015 [29] | Oral hygiene instructions, all kinds of dental treatments, such as fillings and adjustment of overhanging restorations, were completed immediately after patient enrollment, SRP using a reduced Gracey curette set (Gracey, SAS 5-6, SAS 7-8, SAS 11-12, SAS 13-14, Hu-Friedy) with an ultrasonic device (Dentsply/Cavitron, SPS, 30 K, TFI 1000, Dentsply, York, PA, USA) under local anesthesia, endpoint of treatment: a smooth tooth surface, patients received no adjunctive therapy (local or systemic antibiotics, NSAI, laser, ozonotherapy and mouth rinses), an experienced periodontist (EC) performed all treatment procedures (SRP, providing oral hygiene instructions and organizing patient recalls) | SRP in 4 sequential visits with 2 or 3 days intervals completed within 12 days, each appointment lasted 45 min; all patients received monthly periodontal maintenance, including oral hygiene reinforcement, scaling and polishing as necessary | 8 were excluded for several reasons did not return for 3 months follow-up, pregnancy, weight loss |
| Eldin et al. 2013 [30] | Oral hygiene instructions, SRP | n.r.; periodontal maintenance (re-examination) performed weekly for 3 months after therapy | n.r. |
| Gonçalves et al. 2015 [31] | Oral hygiene instructions, Supragingival plaque and calculus removal, exodontia, filling overhang removal and provisional restoration as necessary, trained periodontist performed SRP with manual curets and ultrasonic device under local anesthesia, endpoint for each SRP appointment was “smoothness of the scaled roots.” | 4 to 6 appointments lasting 1 h each, periodontal therapy was completed in 14 days; periodontal maintenance at 3 and 6 months after therapy | 3 patients from the group without obesity and 6 from the group with obesity did not return for the 3-months follow-up visit and were excluded. |
| Goênalves et al. 2015 [32] | Oral hygiene instructions regarding brushing technique and use of dental floss, supragingival plaque and calculus removal, exodontia, provisional restoration and filling overhang removal, as necessary, trained periodontist performed SRP using manual curetes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA), under local anaesthesia, without use of local and/or systemic antimicrobials. | Treatment time; periodontal maintenance 4 to 6 appointments lasting approximately 1 h each, Periodontal therapy completed within 2 weeks; All patients received periodontal maintenance every 3 months post-therapy | Adverse events There were no patient and sampled site dropouts during the course of the study. |
reduction in PPD (mm) at full-mouth sites showed after 3 months a not statistically significant difference ($p = 0.08$) between the obese group compared to the group without obesity. However after 6 months there was a statistically significant difference ($p = 0.04$). At this time point, especially deep sites (PPD $\geq 7$ mm) showed a significantly better result in the group without obesity ($p = 0.04$). Another study of Gonçalves et al. [32] reported that patients with obesity had a significantly greater mean PD (6 months $p$-value = 0.04, 12 months $p$ value = 0.03) than patients without obesity at six and 12 months post-therapy. The data of a study by Suvan et al. [34] corroborated these findings and showed that obesity was an independent impact value of poorer periodontal treatment outcome 2 months after therapy. The extent of the association between poorer periodontal treatment and obesity was similar to that of smoking ($p = 0.02$). They worked with 260 patients. This secondary analysis consisted of individuals participating in five clinical studies of non-surgical periodontal therapy over a 7-year period. Lakkis et al. [33] selected 30 patients who were obese; 15 of them had previously undergone bariatric surgery, whereas the other half ($n = 15$) did not loose any weight and served as a control group. The bariatric surgery group reached a statistically significant greater mean PPD reduction (0.45 mm versus 0.28 mm) compared with the control (no surgery) group ($p = 0.007$; Table 4).
Limitations

Some patients could not be reviewed or discontinued the study for personal reasons [28, 29, 31]. Weight loss and pregnancy were additional reasons to be excluded in the study of Duzagac et al. [29] (Table 7).

The quality of the included studies was evaluated through the Newcastle-Ottawa Quality Assessment Scale (Table 8).

Discussion

This review focused on obesity and the outcome after non-surgical periodontal therapy and has shown that currently there is no really robust scientific evidence to reach solid conclusions and recommendations.

Three papers [8, 29, 30] were found, which did not find any statistically significant negative impact of obesity on the response to non-surgical periodontal therapy, whereas five papers [28, 31–34] showed the opposite, i.e. a clearly negative influence of obesity on the treatment outcomes.

With regard to the quality of evidence, seven included papers [8, 28, 29, 31–34] reported some limitations.

Al-Zahrani et al. [8] included only women. Gonçalves and co-workers [31] did not consistently apply the accepted definitions of overweight and obesity, but rather included the waist-to-hip-ratio (WHR) for their definitions, probably leading to inclusion of patients with a BMI inferior to 30 kg/m² into the obesity group. Thus
the results are difficult to interpret and compare with the other studies and are therefore not applicable for patients with a BMI ≥40 kg/m² [31]. Nonetheless, these studies still show a clearly better tendency with regard to the treatment response for patients without obesity as defined in their study. Lakkis et al. [33] chose another interesting way to find an impact of obesity on the outcome of non-surgical periodontal treatment. They compared obese people who had undergone bariatric surgery (BS) with obese who did not. After weight loss in the BS group, a reduction in total adipocytes might have resulted in a decrease in adipokines and pro-inflammatory mediators released by those adipose cells. This systemic inflammatory reduction might have played a role in reducing the insulin resistance resulting in a better outcome after periodontal therapy as suggested by the authors [33]. Some limitations in the specific profile of the obese patients (nondiabetic, non-smoker) in the paper of Bouaziz et al. [28] may restrict the extrapolation of the results to the whole obese population. Furthermore, the small sample size may also limit the power of this study. Duzagac et al. [29] failed to include a control group of periodontally healthy controls with obesity. Additionally, the mean periodontitis parameters were within the limits of “moderate” periodontitis, and the WHR and BMI values of these obese patients were predominantly below those characterizing morbid obesity. So, the results of this study may not be extrapolated to those with severe periodontitis or morbid obesity. The second included study of Gonçalves and co-workers [32] assumes that the high interpatient variance in adipokine levels may reduce the statistical power to detect treatment effects, as previously reported. The results presented by Suvan et al. [34] may have been influenced by study limitations linked with unequal numbers in BMI categories and sample size. In addition, there may have been limitations with regard to the interpretation associated with the post hoc secondary analysis experimental design, although variation in clinical assessment and treatment was minimized by examiner and treatment clinician stability. This study did not constitute a higher level of evidence in the context of evidence-based health care levels of scientific evidence [34].

Overall, obesity is an obvious, visible stigma so that the studies cannot be considered blinded. This may be another possible bias in each of the studies.

Five studies [8, 28, 29, 31, 32] excluded smokers. Since smoking influences periodontal health these studies are biased [9] and may not be fully representative for the typical overall population. Overall it appears, however, that a positive effect of normal weight is present in non-smokers [28, 31, 32] and in smokers [34].

As mentioned before, the included studies differed in statistical methods, populations, sample sizes, definition of chronic periodontitis, definition of obesity, time of outcome measurement, smoking status, periodontal assessment and non-surgical periodontal therapy. Therefore, it was not only impossible to perform a meta-analysis but also draw clear conclusions. Nonetheless there is a consensus in the studies that obesity is associated with different baseline PPD levels. The large cohort in the study of Suvan et al. [34] and the long term results of Gonçalves et al. [31, 32] may lead to the conclusion that obesity is an important negative factor which influences non-surgical periodontal therapy.

In summary, all studies [8, 28, 29, 31–34] included in this review validated the efficacy of non-surgical periodontal therapy, except the study of Eldin and co-workers [30] who did not report any efficacy of the therapy (Table 3). Clinically, it appears obvious that a therapy is necessary to reach periodontal health independent of the patient’s body mass index.

Because this systematic review provided only moderate evidence that obesity is an important factor for non-surgical periodontal therapy, future prospective cohort studies are needed to confirm these findings [36]. Such trials should be of high methodological quality. They should control important confounding factors such as smoking status, severity of chronic periodontitis, severity of obesity. Every patient should get the same periodontal treatment and periodontal maintenance. Overall, there is a possibility to solve the research question even though the studies still show a clearly better tendency with regard to treatment response for patients without obesity as defined in their study. Overall it appears, however, that a positive effect of normal weight is present in non-smokers [28, 31, 32] and in smokers [34].

Clinicians should know that obesity may have some influence on periodontal status and are likely to have a negative impact on the clinical outcome of conservative treatment, even if this systematic review found only five [28, 31–34] out of eight papers [8, 28–34] corroborating the influence of obesity on the clinical periodontal outcome focusing on PPD as surrogate parameter for periodontal healing.

Clinicians might consider a weight reduction diet as an additional treatment for periodontal health with a positive effect expected after 6 and 12 months [31, 32]. Also it should not be neglected that weight control has substantial other beneficial health effects which on their own justify such a recommendation.

**Conclusion**

This systematic review indicates a possible negative relationship between obesity and poorer treatment outcome in obese patients after non-surgical therapy based on the results of five out of eight studies. Three of these studies denied an impact of obesity on the treatment. The potentially inferior healing response could be based on pathophysiological inflammatory models.

Baseline levels showed also a poorer periodontal health in patients with obesity compared with non-obese patients.
No study found any better dental health parameters in obese than in non-obese individuals, and although dental health may not be the most important target for arranging at a near normal body weight, a person who can keep his or her body weight near normal might, in addition to all other established health benefits, count on having better periodontal health than if they are obese.

Acknowledgment

The authors would like to thank Mrs. Dr. Martina Gestell, librarian of the main library of the University of Zurich who performed the electrical literature search. This study was supported by the Clinic of Preventive Dentistry, Periodontology and Cariology (Center of Dental Medicine) of the University of Zurich.

Authors’ contributions

FAG and PRS conceived the study, participated in its design, did the literature search and drafted the manuscript. PS helped to supervise the methodological correctness of the performed study and the coordination. OAS and JHB provided the required medical theoretical background for this study and participated in the study design. CH helped with the statistical evaluation of the papers and the tables. All authors carefully read and approved the final text.

Competing interest

The authors declare that they have no competing interests.

Author details

1. Clinic of Preventive Dentistry, Periodontology and Cariology, Center of Dental Medicine, University of Zurich, Plattenstrasse 11, CH-8032 Zurich, Switzerland. 2. Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland. 3. Department of Statistics, Ludwig-Maximilians-University of Munich, Munich, Germany.

Received: 28 January 2016 Accepted: 11 August 2016

Published online: 02 September 2016

References

1. Saito T, Shimazaki Y, Koga T, Tsuchi M, Ohshima A. Relationship between upper body obesity and periodontitis. J Dent Res. 2001;80:1631–6.
2. Piscon N, Heng N, Berminouin JP, Kleber BM, Willich NN, Piscon T. Obesity, inflammation, and periodontal disease. J Dent Res. 2007;86:400–9.
3. Francesco Branca HNuTL. Die Herausforderung Adipositas und Strategien zu ihrer Bekämpfung in der Europäischen Region der WHO. 2007.
4. Suresh S, Mahendra J. Multifactorial relationship of obesity and periodontal disease. J Clin Diagn Res. 2014;8:ZE01–3.
5. Saito T, Shimazaki Y, Koga T, Tsuzuki M, Ohshima A, Koga T, et al. Relationship between obesity and periodontal disease in patients with type 2 diabetes and chronic periodontitis. J Clin Periodontol. 2008;35:380–7.
6. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366:1649–50.
7. Sotiriou S. Host response, obesity, and oral health. Cent Eur J Immunol. 2015;40:201–5.
8. Al-Zahrani MS, Alghamdi HS. Effect of periodontal treatment on serum C-reactive protein level in obese and normal-weight women affected with type 2 diabetes. J Periodontol. 2007;78:684–9.
9. Nishida NTM, Hayashi N, Nagata H, Takeshita T, Nakayama K, et al. Determination of smoking and obesity as periodontitis risks using the classification and regression tree method. J Periodontol. 2005;76:923–8.
10. Perelstein MI, Bissada NF. Influence of obesity and hypertension on the severity of periodontitis in rats. Oral Surg Oral Med Oral Pathol. 1997;83:707–19.
11. Koletsy S. Obese Spontaneously Hypertensive Rats-A Model for Study of Atherosclerosis. Exp Mol Pathol. 1973;19:53–60.
12. Chaffee BW, Weston SJ. Association between chronic periodontal disease and obesity: a systematic review and meta-analysis. J Periodontol. 2010;81:1708–24.
13. Wimmer GPB. A critical assessment of adverse pregnancy outcome and periodontal disease. J Clin Periodontol. 2008;35:380–97.
14. Blairot A, Vergnes JN, Nuxwaneer S, Amar J, Siou M. Periodontal diseases and cardiovascular events: meta-analysis of observational studies. Int Dent J. 2009;59:197–209.
15. Tomar SL, Arora S. Smoking-attributable periodontitis in the United States: findings from NHANES III. National Health and Nutrition Examination Survey. 2000;71:743–51.
16. Tonetti MS. Cigarette smoking and periodontal diseases: etiology and management of disease. Ann Periodontol. 1998;188–101.
17. Arnaud Chiolero DF, Fred P, Jacques C. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2002;88:1801–9.
18. Fei Xu, BEcon, Xiao-Mei Yin BM, Youfa Wang. The association between amount of cigarettes smoked and overweight, central obesity among Chinese adults in Nanjing, China. Asia Pac J Clin Nutr. 2007;16:240-247.
19. Hou X, Jia W, Bao Y, Lu H, Jiang S, Gu H, Xiang K. Risk factors for overweight and obesity, and changes in body mass index of Chinese adults in Shanghai. BMC Public Health. 2008;8:389.
20. Altay U, Gurgan CA, Agbahi K. Changes in inflammatory and metabolic parameters after periodontal treatment in patients with and without obesity. J Periodontol. 2013;84:13–23.
21. David Harko AL, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta- Analyses: The PRISMA Statement. J Clin Epidemiol. 2009;62:1006-12.
22. Buset S, Zittmann NLI, Weiger R, Walter C. Non-surgical periodontal therapy supplemented with systemically administered azithromycin: a systematic review of RCTs. Clin Oral Investig. 2015;19(8):1763–75.
23. D’Alfio F, Nibali L, Parkar M, Suzen J, Tonetti MS. Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res. 2005;84:269-73.
24. Duan FY, O-YX, Zhou YX. Effect of periodontal initial therapy on the serum level of lipid in the patients with both periodontitis and hyperlipidemia. Beijing Da Xue Xue Bao. 2009;41:36-39.
25. Iwamoto Y, Nishimura F, Sgura Y, Takeuchi K, Kurihara M, Takashita S, et al. Antimicrobial periodontal treatment decreases serum C-reactive protein, tumor necrosis factor-alpha, but not adiponectin levels in patients with chronic periodontitis. J Periodontol. 2003;74:1231–6.
26. Kardejer WN, Cetinikalp S, Kinane DF. Adipokines and inflammatory mediators after initial periodontal treatment in patients with type 2 diabetes and chronic periodontitis. J Periodontol. 2010;81:24–33.
27. Tandon S, Lamba AK, Verru M, Munjal A, Faraz F. Effect of Periodontal Therapy on Serum Lipid Levels. Indian J Med. 2010;1:19–25.
28. Bouaziz W, Davideau JL, Tenenbaum H, Huck O. Adiposity Measurements and Non-Surgical Periodontal Therapies. J Periodontol. 2013;86:1030–7.
29. Duzagac E, Ciftcibasi E, Erdem MG, Karabey V, Kasali K, Badur S, et al. Is obesity associated with healing after non-surgical periodontal therapy? A local vs. systemic evaluation. J Periodontal Res. 2015. [Epub ahead of print]
30. Eldin AM, Nasr SA, Hassan NE. Effect of non-surgical periodontal therapy on interleukin-8/II-lb level in gingival crevicular fluid in overweight and obese subjects with chronic periodontitis. World J Med Sci. 2013;9:173–9.
31. Goncalves TE, Feres M, Zimmermann GS, Faveri M, Figueiredo LC, Braga PG, et al. Effect of scaling and root planing on clinical response and serum levels of adipocytokines in patients with obesity and chronic periodontitis. J Periodontol. 2015;86:53–61.
32. Goncalves TE, Zimmermann GS, Figueiredo LC, Souza Mde C, da Cruz DF, Bastos MF, et al. Local and serum levels of adipokines in patients with obesity after periodontal therapy: one-year follow-up. J Clin Periodontol. 2015;42:431–9.
33. Lakkis D, Bissada NF, Saber A, Khaitan L, Palomo L, Narendran S, et al. Response to periodontal therapy in patients who had weight loss after bariatric surgery and obese counterparts: a pilot study. J Periodontol. 2012;83:684–9.
34. Susan J, Petrie A, Molea DR, Nibali L, Patel K, Darbar U, et al. Body mass index as a predictive factor of periodontal therapy outcomes. J Dent Res. 2014;93:49–54.
35. Genco RJ, Ho A, Nishimura F, Murayama Y. A proposed model linking inflammation to obesity, diabetes, and periodontal infections. J Periodontol. 2005;76:2075–84.
36. Sgołastra F, Severino M, Pietropaoli D, Gatto R, Monaco A. Effectiveness of Periodontal Treatment to Improve Metabolic Control in Patients With Chronic Periodontitis and Type 2 Diabetes: A Meta-Analysis of Randomized Clinical Trials. J Periodontol. 2013;84:958–73.
37. Europerio 4, Berlin, Germany, 19–21 June 2003. J Clin Periodontol. 2003;30:100–5.
38. Abstracts for the Royal Australian and New Zealand College of Psychiatrists 40th Congress. Psychiatry in a Changing World, Sydney, Australia, Sunday, 22–Thursday 26, May 2005. Aust N Z J Psychiatry. 2005;39:A97–186.
39. 5th Joint Meeting of the European Tissue Repair Society and the Wound Healing Society. Wound Repair Regen. 2009;17:AS5–47.
40. Recently published abstracts. Altern Med Rev. 2010;15:369–80.
41. DENTSPly. Posters. J Dent Hyg. 2012;86:322–6.
42. HealthBeat. Dent Assist. 2007;76:659–63. S5p.
43. Abstracts for Poster Presentations. 2nd North American/Global Dental Hygiene Research Conference Bethesda, MD, October 20–22, 2011. J Dent Hyg. 2012;86:39–53. 15p.
44. Abstracts for the International Symposium on Dental Hygiene, Cape Town, South Africa, August 14–17, 2013. Int J Dent Hyg. 2013;11:156–73.
45. Abou Sulaiman AE, Shehadeh RM. Assessment of Total Antioxidant Capacity and the Use of Vitamin C in the Treatment of Non-Smokers With Chronic Periodontitis. J Periodontol. 2010;81:1547–54.
46. Acharaya A, Bhavsar N, Jadav B, Parikh H. Cardioprotective effect of periodontal therapy in metabolic syndrome: a pilot study in Indian subjects. Metab. 2010;8:335–41.
47. Akpınar A, Toker H, Ozdemir H, Bostanci V, Aydin H. The effects of non-surgical periodontal therapy on oxidant and antioxidant status in smokers with chronic periodontitis. Arch Oral Biol. 2013;58:717–23.
48. Armstrong BL, Sensat ML, Stoltenberg JL. Halitosis: a review of current literature. J Dent Hyg. 2010;84:465–74.
49. Arora N, Avula H, Avula JK. The adjunctive use of systemic antioxidant therapy (lycopene) in nonsurgical treatment of chronic periodontitis: A Short-term evaluation. Quintessence Int. 2013;44:399–409.
50. Basesgmez C, Berber L, Yalcin F. Clinical and Biochemical Efficacy of Minocycline in Nonsurgical Periodontal Therapy: A Randomized Controlled Pilot Study. J Clin Pharmacol. 2011;51:915–22.
51. Bresolin AC, Pronsatti MM, Pasqualotto LN, Nassar PO, Jorge AS, da Silva EAA, et al. Lipid profiles and inflammatory markers after periodontal treatment in children with congenital heart disease and at risk for atherosclerosis. Vasc Health Risk Manage. 2013;9:703–9.
52. Bresolin AC, Pronsatti MM, Pasqualotto LN, Nassar PO, Jorge AS, da Silva EAA, et al. Effectiveness of periodontal treatment on the improvement of inflammatory markers in children. Arch Oral Biol. 2014;59:639–44.
53. Casperse CI, Thomas GD, Roseman LA, Beckles GL, Albright AL. Aging, Diabetes, and the Public Health System in the United States. Am J Public Health. 2012;102:1482–97.
54. Càula AL, Lira-Junior R, Tinoco EM, Fischer RG. The effect of periodontal therapy on cardiovascular risk markers: a 6-month randomized clinical trial. J Clin Periodontol. 2014;41:875–82.
55. Chapple ILC. Oxidative stress, nutrition and neurogenomics in periodontal health and disease. Int J Dent Hyg. 2006;4:15–21.
56. Chapple ILC, Brock GR, Milward MR, Ling N, Matthews JB. Compromised GCF total antioxidant capacity in periodontic: cause or effect? J Clin Periodontol. 2007;34:103–10.
57. Chandni R, Mammen J, Joseraj MG, Joseph R. Effect of Nonsurgical Periodontal Therapy on Insulin Resistance in Patients with Type 2 Diabetes Mellitus and Chronic Periodontitis. Diabetes. 2015;64:A692.
58. Chaston R, Sabatini R, Koertge TE, Brooks CN, Schenkein HA. Serum anticholinergic concentrations in patients with chronic periodontitis following scaling and root planing. J Periodontol. 2014;85:683–7.
59. Chee HK, Lim LP, Tay F, Thai AC, Sum CF. Non-surgical periodontal treatment and lipid levels in diabetic patients. Ann R Australas Coll Dent Surg. 2008;19:183.
60. Chee B, Park B, Bartold P. Periodontitis and type II diabetes: a two-way relationship. Int J Evid-Based Healthcare. 2013;11:317–29. S13p.
61. Chen L, Luo G, Xuan D, Wei B, Liu F, Li J, et al. Effects of non-surgical periodontal therapy on clinical response, serum inflammatory parameters, and metabolic control in patients with type 2 diabetes: a randomized study. J Periodontol. 2012;83:435–43.
62. D’Aiuto F, Parkar M, Andreou G, Brett PM, Ready D, Tonetti MS. Periodontitis and atherogenesis: causal association or simple coincidence? A pilot intervention study. J Clin Periodontol. 2004;31:402–11.
89. Hovifar-Delozier CA. A common voice. Access. 2008;22:22–9.
90. Ide M, Jagdev D, Coward PY, Crook M, Barclay GR, Wilson RF. The short-term effects of treatment of chronic periodontitis on circulating levels of endotoxin, C-reactive protein, tumor necrosis factor-alpha, and interleukin-6. J Periodontol. 2004;75:620–8.
91. Ide M. Intensive periodontal treatment including extractions is associated with more immediate systemic inflammation but improved longer-term endothelial function compared to simple scaling. J Evid Based Dent Pract. 2007;7:162–4. 163p.
92. Jahn C. Diabetes and periodontal health. Dent Assit. 2004;73:24–9.
93. Jahn C. STANDARDS. Standard 1: Assessment. III. Risk Assessment. Access. 2015;29:19–23. 15p.
94. Jaiswal GR, Jain VK, Dhodapkar SV, Kumathalli KL, Kumar R, Nemawat A, et al. Impact of bariatric surgery and diet modification on periodontal status: A six month cohort study. J Clin Diagn Res. 2015;9:243–5.
95. Janket S. Scaling and root-planing (SRP) may improve glycemic control and lipid profile in patients with chronic periodontitis (CP) and type 2 diabetes (DM2) in a specific subgroup: a meta-analysis of randomized clinical trials. J Evid Based Dent Pract. 2014;14:31–3.
96. Jared H, Bogess KA. Periodontal diseases and adverse pregnancy outcomes: a review of the evidence and implications for clinical practice. J Dent Hyg. 2008;82:24–41.
97. Jiang H, Xiong X, Su Y, Zhang Y, Wu H, Jiang Z, et al. A randomized controlled trial of pre-conception treatment for periodontal disease to improve periodontal status during pregnancy and birth outcomes. BMC Pregnancy Childbirth. 2013;13:228.
98. Kamal Al Habashneh R, Khader Y, Al Bayati L, Taani D. Effects of nonsurgical periodontal therapy on C-reactive protein and serum lipids in Jordanian adults with advanced periodontitis. J Periodontal Res. 2011;46:616–21.
99. Kamtof KP. Relationship between chronic periodontitis clinical manifestation and lipid peroxidation in saliva. Uzbekiston Tibbiet Zhurnal. 1998:037–9.
100. Kapellas K, Do LG, Mark Bartold P, Siliton MR, Maple-Brown LJ, O’Dea K, et al. Effects of full-mouth scaling on the periodontal health of Indigenous Australians: a randomized controlled trial. J Clin Periodontol. 2013;40:1016–24.
101. Keller A, Rohde JF, Raymond K, Heitmann BL. Association between periodontal disease and overweight and obesity: a systematic review. J Periodontol. 2015;86:766–76.
102. Klany F, Hedayat A. Evaluation of serum anti-cardiolipin antibodies after non-surgical periodontal treatment in chronic periodontitis patients. Odontologica. 2014;103:203–9.
103. Klany F, Hedayat A. Evaluation of serum anti-cardiolipin antibodies after non-surgical periodontal treatment in chronic periodontitis patients. Odontologica. 2015;103:203–9.
104. Kipp A, Majerski J. New trends in peri. Access. 2003;17:10–5.
105. Kudva P, Tabasum ST, Garg N. Evaluation of clinical and metabolic changes after non surgical periodontal treatment of type 2 diabetes mellitus patients: A clinico biochemical study. J Indian Soc Periodontol. 2010;14:257–62.
106. Kumar M, Bandopadhyay P, Mishra L, Das S, Kundu PK, Mistry S. Effect of periodontal therapy on glycemic control and circulating TNF-a in type 2 diabetic patients. Int J Diabetes Ctries. 2015;35:96–102.
107. Kurti B, Tüiter G, Serdar M, Pinar S, Demirel I, Töyüm. Gingival crevicular fluid prostaglandin E(2) and thioarbituric acid reactive substance levels in smokers and non-smokers with chronic periodontitis following phase I periodontal therapy and adjunctive use of flurbiprofen. J Periodontol. 2007;78:104–11.
108. Kurtis B, Tuter G, Serdar M, Pinar S, Demirel I, Töym. Gingival crevicular fluid prostaglandin E-2 and thioarbituric acid reactive substance levels in smokers and non-smokers with chronic periodontitis following phase I periodontal therapy and adjunctive use of flurbiprofen. J Periodontol. 2007;78:104–11.
109. Lee HJ, Jun JK, Lee SM, Ha JE, Paik DI, Bae KH. Association between obesity and periodontitis in pregnant females. J Periodontol. 2014;85:e224–231.
110. Li X, Tse HF, Yiu KH, Zhan C, Jin LJ. Periodontal therapy decreases serum levels of adipocyte fatty acid-binding protein in systemically healthy subjects: a pilot clinical trial. J Periodontal Res. 2013;48:308–14.
111. Ling A, Wang P-W, Lin R-T, Hsieh C-I, Lee P-Y, Zhuang R-Y, et al. Evaluation of Periodontal Status and Effectiveness of Non-Surgical Treatment in Patients With Type 2 Diabetes Mellitus in Taiwan for a 1-Year Period. J Periodontol. 2012;83:621–8.
112. Lo JC, O’Ryan F, Yang J, Harahar MK, Gonzales JR, Gordon N, et al. Oral Health Considerations in Older Women Receiving Oral Bisphosphonate Therapy. J Am Geriatr Soc. 2011;59:916–22. 917p.
113. Malhotra R, Kapoor A, Grover V, Grover D, Kaur A. Effect of Scaling and Root Planing on Erythrocyte Count, Hemoglobin and Hematocrit in Patients with Chronic Periodontal Disease. J Dent Hyg. 2012;86:195–203.
114. Mant CA, Kirsner RS, Ajdic D. Wound biolifs: Lessons learned from oral biolifs. Wound Repair Regen. 2013;21:352–62.
115. Martinez GL, Koury JC, Bito F, Fischer RG, Gustafsson A, Figueroed CM. The impact of non-surgical periodontal treatment on serum levels of long chain-polyunsaturated fatty acids: a pilot randomized clinical trial. J Periodontal Res. 2014;49:268–74.
116. Martinez GL, Koury JC, Martins MA, Nogueira F, Fischer RG, Gustafsson A, et al. Serum level changes of long chain-polyunsaturated fatty acids in patients undergoing periodontal therapy combined with one year of omega-3 supplementation: a pilot randomized clinical trial. J Periodontal Implant Sci. 2014;44:169–77.
117. Matlock J, Ferguson K, Calef J, Abbott S. Obesity and Bariatric Surgery: Effects on the Oral Cavity. Access. 2012;26:8–11.
118. McDaniel JC, Roy S, Wilgus TA. Neutrophil activity in chronic venomous leg ulcers–A target for therapy? Wound Repair Regen. 2013;21:339–9. 313p.
119. Mehranwade VW, Gayathri GV, Mehta DS. Effects of scaling and root planing with or without a local drug delivery system on the gingival crevicular fluid leptin level in chronic periodontitis patients: a clinico-biochemical study. J Periodontal Implant Sci. 2014;44:118–25.
120. Merchant AT. Hemoglobin A1c levels among patients with diabetes receiving nonsurgical periodontal treatment [1]. JAMA. 2014;311:1919.
121. Michalowicz BS, Hyman L, Wei H, Oates J Jr, Reddy M, Parquette DW, et al. Factors associated with the clinical response to nonsurgical periodontal therapy in people with type 2 diabetes mellitus. JADA. 2014;145:1227–39. 1213p.
122. Mizrak T, Cunca GN, Caglayan I, Balci TA, Aktar GS, Ipek F. Effect of a controlled-release chlorhexidine chip on clinical and microbiological parameters and prostaglandin E-2 levels in gingival crevicular fluid. J Periodontol. 2006;77:437–43.
123. Moeintaghavi A, Arab HR, Bozorgnia Y, Kianoush K, Alizadeh M. Non-surgical periodontal therapy affects metabolic control in diabetics: a randomized controlled clinical trial. Aust Dent J. 2012;57:31–37.
124. Moravec LJ, Boyd LD. Bariatric Surgery and Implications for Oral Health: A CoI. Report. J Dent Hyg. 2011;85:166–76.
125. Muthu J, Muthanandam S, Mahendra J, Narasimayya A, John L, Logarajini A. Effect of Nonsurgical Periodontal Therapy on the Glycaemic Control of Nondiabetic Periodontitis Patients: A Clinical Biochemical Study. Oral Health Prev Dent. 2015;13:261–6.
126. Nassar PO, Walker CS, Salvador CS, Felpetti FA, Orsco SRP, Nassar CA. Lipid profile of people with Diabetes mellitus type 2 and periodontal disease. Diabetes Res Clin Pract. 2012;96:35–9.
127. Newton KM, Chaudhari M, Barlow WE, Inge RE, Theis MK, Spangler LA, et al. A population-based study of periodontal care among those with and without diabetes. J Periodontol. 2011;82:1650–6.
128. Nichols FC, Levinbook H, Shnaydman M, Goldschmidt J. Prostaglandin E2 secretion from gingival fibroblasts treated with interferon-β/ep: effects of lipid extracts from Porphyromonas gingivalis or calculus. J Periodontal Res. 2001;36:142–2001.
129. Nielsen D, Walser C, Kodan G, Chaney RD, Yonkers T, VerSteeg JD, et al. Effects of treatment with clindamycin hydrochloride on progression of canine periodontal disease after ultrasonic scaling. Vet Ther. 2000;1:150–8.
130. Novakovic N, Calic S, Todoric T, Raicevic BA, Dozic I, Petrovic V, et al. Antioxidant Status of Saliva before and after Non-Surgical Periodontal Treatment. Srp Ak Odontol. 2013;61:163–8.
131. Novakovic N, Todoric T, Ricic M, Milinkovic I, Dozic I, Jankovic S, et al. Sialivary antioxidants as periodontal biomarkers in evaluation of tissue status and treatment outcome. J Periodontal Res. 2014;49:129–36.
132. Oliveira AM, de Oliveira PA, Cota LO, Magalhaes CS, Moreira AN, Costa FO. Periodontal therapy and risk for adverse pregnancy outcomes. Clin Oral Investig. 2011;15:609–15.

133. Olsen NC. Health Access. 2006;20:56–7. 52p.

134. Paquette DW, Ryan ME, Wilder RS. Locally delivered antimicrobials: clinical evidence and relevance. J Dent Hyg. 2008;82:10–5.

135. Perayil J, Suresh N, Fenol A, Vyloppillil R, Bhaskar A, Menon S. Comparison of HbA1c Levels in Non-Diabetic Healthy Subjects and Subjects With Periodontitis Before and After Non-Surgical Periodontal Therapy. J Periodontol. 2014;85:1658–66.

136. Perayil J, Suresh N, Fenol A, Vyloppillil R, Bhaskar A, Menon S. Comparison of glycated hemoglobin levels in individuals without diabetes and with and without periodontitis before and after non-surgical periodontal therapy. J Periodontol. 2014;85:1658–66.

137. Phillips A. Oral complications of diabetes: an under-recognized condition. Pract Nurs. 2013;24:562–6.

138. Pradeep AR, Manjunath SG, Swati PP, Shikha C, Sujatha PB. Gingival crevicular fluid levels of leukotriene B4 in periodontal health and disease. J Periodontol. 2007;78:2325–30.

139. Price T. Periodontal disease and adverse pregnancy outcomes: treatment recommendations for the pregnant woman. Access. 2010;24:20–3.

140. Qiqiang L, Huanxin M, Xuejun G. Longitudinal study of volatile fatty acids in the gingival crevicular fluid of patients with periodontitis before and after nonsurgical therapy. J Periodontal. 2012;47:740–9.

141. Radalshafar G, Torabi F, Mirfarshadi N. Short-term effects of intensive non-surgical periodontal therapy and low-dose doxycycline on serum levels of IL-6, TNF-alpha, and lipid profile in advanced periodontitis. Afr J Microbiol Res. 2012;6:355–60.

142. Radnai M, Pal A, Novak T, Urban E, Eller J, Gorzo I. Benefits of periodontal therapy when preterm birth threatens. J Dent Res. 2009;88:280–4.

143. Raghavendra NM, Pradeep AR, Kathariya R, Sharma A, Rao NS, Naik SB. Effect of non-surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease. Dis Markers. 2012;32:383–8.

144. Ramirez JH, Arce RM, Contreras A. Periodontal treatment effects on serum leptin, interleukin-6, and C-reactive protein. J Int Soc Prev Community Dent. 2015;29:49–56.

145. Rasch MS, Mealey BL, Prihoda TJ, Woodard DS, McManus LM. The effect of periodontal therapy when preterminal pregnancy threatens. J Dent Res. 2011;10:953–8.

146. Ramyg J, Halkjær J, Gerber J. Longitudinal associations between periodontitis and total mortality in a Danish population. J Periodontol. 2011;82:1083–90.

147. Saffi MA, Furtado MV, Montenegro MM, Ribeiro IW, Kampits C, Rabelo-Silva AC, et al. Effect of non-surgical periodontal therapy on interleukin-6 and TNF-alpha. J Periodontol. 2012;83:1183–91.

148. Sengupta S, Fine J, Wu-Wang CY, Gordon J, Khokhar A, et al. PPARα ligands and inflammation in health and disease. J Clin Invest. 2011;121:2630–41.

149. Shimada Y, Komatsu Y, Ikezawa-Suzuki I, Tai H, Sugita N, Yoshie H. The effect of periodontal treatment on serum leptin, interleukin-6, and C-reactive protein. J Periodontol. 2010;81:1118–23.

150. Sengupta S, Fine J, Wu-Wang CY, Gordon J, Khokhar A, et al. PPARα ligands and inflammation in health and disease. J Clin Invest. 2011;121:2630–41.

151. Singh N, Narula SC, Sharma RK, Tewari S, Sehgal PK. Vitamin E Supplementation, Superoxide Dismutase Status, and Outcome of Scaling and Root Planing in Patients With Chronic Periodontitis: A Randomized Clinical Trial. J Periodontol. 2014;85:242–9.

152. Siqueira MAD, Fischer RG, Pereira NR, Martins MA, Moss MB, Mendes-Ribeiro AC, et al. Effects of non-surgical periodontal treatment on the L-arginine-nitric oxide pathway and oxidative status in platelets. Exp Biol Med. 2013;238:713–22.

153. Stewart JE, Wager KA, Friedlander AH, Zadeh HH. The effect of periodontal treatment on glycemic control in patients with type 2 diabetes mellitus. J Clin Periodontol. 2001;28:306–10.

154. Talbert J, Elter J, Jared HL, Offenbacher S, Southerland J, Wilder RS. The effect of periodontal therapy on TNF-alpha, IL-6 and metabolic control in type 2 diabetics. J Dent Hyg. 2006;80:7–7.

155. Tamaki N, Tomofuji T, Ekiu D, Yamanaka R, Yamamoto T, Morita M. Short-Term Effects of Non-Surgical Periodontal Treatment on Plasma Level of Reactive Oxygen Metabolites in Patients With Chronic Periodontitis. J Periodontol. 2009;80:901–6.

156. Tamaki N, Tomofuji T, Ekiu D, Yamanaka R, Morita M. Periodontal treatment decreases plasma oxidized LDL level and oxidative stress. Clin Oral Investig. 2011;15:953–8.

157. Tanaka S, Tanaka K, Araki T, Iwata Y, Yamasue H, et al. Effects of non-surgical periodontal therapy on serum lipids and C-reactive protein among hyperlipidemic patients with chronic periodontitis. J Int Soc Prev Community Dent. 2011;29:49–56.

158. Tanaka S, Tanaka K, Araki T, Iwata Y, Yamasue H, et al. Effects of non-surgical periodontal therapy on serum lipids and C-reactive protein among hyperlipidemic patients with chronic periodontitis. J Int Soc Prev Community Dent. 2011;29:49–56.

159. Teles FR, Teles RP, Martin L, Socransky SS, Haffajee AD. Relationships among interleukin-6, tumor necrosis factor-alpha, adipokines, vitamin D, and chronic periodontitis. J Periodontol. 2012;83:1183–91.

160. Teles FR, Teles RP, Martin L, Socransky SS, Haffajee AD. Relationships among interleukin-6, tumor necrosis factor-alpha, adipokines, vitamin D, and chronic periodontitis. J Periodontol. 2012;83:1183–91.

161. Toker H, Akpinar A, Aydin H, Poyraz O. Influence of smoking on interleukin-1beta level, oxidant status and antioxidant status in gingival crevicular fluid from chronic periodontitis patients before and after periodontal treatment. J Periodontal. 2012;47:572–7.

162. Tuter G, Kurtis B, Serdar M, Akyan T, Okuyk Y, Kuyuc A, et al. Effects of scaling and root planing and sub-antimicrobial dose doxycycline on oral and systemic biomarkers of disease in patients with both chronic periodontitis and coronary artery disease. J Clin Periodontol. 2007;34:673–81.

163. Tawfik A, Baylar I, Huseyinov A. Effects of selective cyclooxygenase-2 inhibition on gingival tissue levels of prostaglandin E2 and prostaglandin F2alpha and clinical parameters of chronic periodontitis. J Periodontol. 2003;74:57–63.

164. Van Dyke TE, Hasturk H, Kantarci A, Freire MO, Nguyen D, Dalli J, et al. Proresolving nanomedicines activate bone regeneration in drug-eluting scaffolds. J Dent Res. 2015;94:148–55.

165. Vyas SP, Sihorkar V, Mishra V. Controlled and targeted drug delivery strategies towards intraperiosteal pocket diseases. J Clin Pharm Ther. 2000;25:21–42.

166. Wahid A, Chaudhry S, Ehsan A, Butt S, Khan AA. Bidirectional relationship between chronic kidney disease & periodontal disease. Pak J Med Sci. 2013;29:211–5.

167. Wang XE, Xu L, Meng HX, Lü D, Chen ZB, Lu RF. Long-term clinical and hemoglobin A1c level, in patients with diabetes mellitus. J Clin Bio Med. 2013;238:713–22.

168. Wehmeyer MM, Kishiragar AV, Barros SP, Beck JD, Moss KL, Preisser JS, et al. A randomized controlled trial of intensive periodontal therapy on metabolic and inflammatory markers in patients With ESRD: results of an exploratory study. Am J Kidney Dis. 2011;58:4150–50.

169. Wei D, Zhang XL, Wang YZ, Yang CX, Chen G. Lipid peroxidation levels, total oxidant status and superoxide dismutase in serum, saliva and gingival crevicular fluid in chronic adult periodontitis patients and after periodontal therapy. J Periodontol. 2010;81:93–5.

170. Wilde MB. Periodontal disease and type 2 diabetes. J Dent Hyg. 2009;38:34–44.

171. Wilde MB. Periodontal disease and type 2 diabetes. J Dent Hyg. 2009;38:34–44.

172. Wilde MB. Periodontal disease and type 2 diabetes. J Dent Hyg. 2009;38:34–44.

173. Wilde MB. Periodontal disease and type 2 diabetes. J Dent Hyg. 2009;38:34–44.

174. Wilde MB. Periodontal disease and type 2 diabetes. J Dent Hyg. 2009;38:34–44.

175. Wilde MB. Periodontal disease and type 2 diabetes. J Dent Hyg. 2009;38:34–44.
176. Zuza EP, Barroso EM, Carrareto AL, Pires JR, Carlos IZ, Theodoro LH, et al. The role of obesity as a modifying factor in patients undergoing non-surgical periodontal therapy. J Periodontol. 2011;82:676–82.

177. Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontology 2000. 2004;34:9–21.

178. Silness J, Löe H. Periodontal Disease in Pregnancy II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand. 1964;22:121–35.

179. Löe HSJ. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand. 1963;21:533–51.